ReviewBiomedicines2022

Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.

Ray Manneh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.